ArticleYonsei medical journal2025
Gene Expression Profiling and Pathway Analysis of the Effect of Dienogest on Ovarian Endometriosis: A Comparative Study.
Article in Yonsei medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Evidence and Emerging Directions in Endometriosis Pharmacotherapy: A Systematic Review of Recent Advances.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeEndometriosis affects about 10% of reproductive-age women and can be managed through medical treatments, surgical intervention, or both. Approximately 40%-50% of patients experience recurrence within 5 years after surgery. Therefore, medical treatments, especially progestins, play a major role in the management of endometriosis. Dienogest has been used to treat endometriosis; however, its effects on endometriosis remain unclear. This study aimed to evaluate the molecular effects of dienogest on endometriosis. MATERIALS AND
methodsThe enrolled patients were aged ≥20 years, premenopausal, and had pathologically confirmed endometriosis. The study participants consisted of four women who had received dienogest treatment before surgery and four women who had not received any medical treatment before surgery. This study compared the RNA profiles of the dienogest-treated and untreated groups before surgery.
resultsWe identified 406 differentially expressed genes by comparing the dienogest-treated and untreated groups and conducted enrichment analysis with an adjusted
conclusionComparison of the dienogest-treated and untreated groups before endometriotic ovarian cyst surgery revealed pathways related to immune system function, inflammatory response, cell signaling and adhesion, and metabolic regulation. These findings suggest that dienogest may play a role in controlling inflammation and immune regulation, potentially alleviating endometriosis-related symptoms and delaying recurrence. Although further studies are required for validation, our preliminary findings suggest that dienogest may contribute to delaying the progression from endometriosis to carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.